On 28th April Ascendis Pharma announced the exciting news that the MHRA had approved their new parathyroid hormone ‘Yorvipath’ specifically as a treatment for chronic hypoparathyroidism in adults in the UK.
You can read their press release here https://investors.ascendispharma.com/news-releases/news-release-details/united-kingdoms-mhra-approves-yorvipathr-palopegteriparatide
If you are a registered member of Parathyroid UK you will, by now, have received an email with further information.